Oral arginine and insulin secretion
US6143786A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 2, 1999 |
| Grant date | Nov 7, 2000 |
| Priority date | — |
| Expiry date | Feb 2, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA23L33/175
- WIPO fieldFood chemistry
- WIPO sectorChemistry
Abstract
A therapeutically effective amount of L-arginine, or a physiologically acceptable salt thereof, is orally administered, preferably as a food supplement in combination with a meal approved by the American Diabetes Association Inc. ("ADA"), to a person having Type II diabetes mellitus but who is not on either insulin or other medication for glycemic control. When 3 g to 15 g of L-arginine is ingested concurrently with a meal, or immediately prior to eating a meal, the L-arginine decreases the concentration of insulin generated, compared to that generated after the same meal without the L-arginine; at the same time, concentration of glucose in the person's blood is decreased, indicating that available insulin sensitizes cells so as to nearly mimic the effectiveness of normal cells in a non-diabetic person; from 3 g to 15 g of orally ingested L-arginine, by itself, produces no measurable increase in insulin secretion in a diabetic.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.